News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
92
Sources here
3
Companies here
1
Search results Stored financial headlines

Active search

92 matching headlines

Ticker or company: LILY34Main company stories
Clear
Latest

finance.yahoo.com Earnings

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer

Chicago, IL – August 17, 2026 – Today, Zacks Equity Research discusses Eli Lilly LLY, Johnson & Johnson JNJ and Bayer BAYRY. Industry: Large Cap Pharmaceuticals Link to article: https://www.zacks.com/commentary/2974767/3-large-cap-stocks-to-watch-as-pharma-recovery-takes-hold 3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold The drug and biotechnology sector has had a strong recovery so far in 2026, driven by innovation, robust …

Main company 🇧🇷 Brazil
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient

Eli Lilly (NYSE: LLY) has been posting outstanding financial results over the past few years. The company owes this success partly to its work in the weight-loss market. Eli Lilly's Zepbound is the leader in this niche and is growing sales rapidly. However, some …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly’s Weight-Loss Pill Just Got Its First Foothold in Europe

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain's drug regulator authorized the company's oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Can Veeva Systems Inc. (VEEV)’s AI Platform Keep Pace With Eli Lilly and Company (LLY)’s Explosive Growth

On August 11, Veeva Systems Inc. (NYSE:VEEV) announced that Eli Lilly and Company (NYSE:LLY) committed to deploying Veeva Vault CRM globally. Vault CRM serves as the core infrastructure for "agentic commercial," Veeva's AI-driven commercial framework designed to modernize field engagement and speed medicine delivery. …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly (LLY) Steps Up Legal Fight Over Illegal Retatrutide Sales

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE: LLY) has intensified legal action against U.S. entities accused of selling …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains

While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

IBD 50 Stocks To Watch: Obesity Drug Giant Eli Lilly Offers New Buy Point

Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens. Continue Reading

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
seekingalpha.com Regulatory and legal Main company 🇧🇷 Brazil

Lilly files six lawsuits to crack down on black market retatrutide weight-loss shots

[Lilly Biotechnology Center in San Diego, California, USA.] JHVEPhoto Lilly escalated its fight against black-market retatrutide by filing six new lawsuits against U.S. sellers, including compounding pharmacies, medical spas, and online vendors, the drugmaker said Wednesday in a statement [https://seekingalpha.com/pr/20616057-lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal]. The company said retatrutide …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?

The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Analyst action Main company 🇧🇷 Brazil

Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Regulatory and legal Main company 🇧🇷 Brazil

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Lifespan Vision Ventures Leads Remedium Bio's Series A Financing

Investment supports advancement of Remedium's durable protein therapeutics platform toward first-in-human clinical development. NORWALK, Conn., Aug. 10, 2026 /PRNewswire/ -- Lifespan Vision Ventures today announced that it is leading Remedium Bio, Inc.'s ("Remedium") $10 million Series A financing and has completed the round's initial …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook

Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

LLY Q2 Deep Dive: Key Products and Pipeline Expansion

Global pharmaceutical company Eli Lilly (NYSE:LLY)reported Q2 CY2026 results topping the market's revenue expectations , with sales up 47.7% year on year to $22.97 billion. The company's full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts' estimates. Its non-GAAP …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

BofA points to the Eli Lilly market that could outsize the U.S.

Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly and Company Q2 Earnings Call Highlights

Key Points Interested in Eli Lilly and Company? Here are five stocks we like better. Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales. The company raised its full-year revenue outlook to $85 billion–$87 …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

CVS Health (CVS) Is Down 8.6% After Raising 2026 Guidance And Expanding GLP-1 Tie-Up With Lilly – Has The Bull Case Changed?

In early August 2026, CVS Health reported second-quarter results showing higher sales of US$35,117 million and revenue of US$106.10 billion, alongside net income of US$2,979 million and materially higher earnings per share versus a year earlier. On the same day, CVS Health also raised …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

The Bull Case For Eli Lilly (LLY) Could Change Following Raised 2026 Guidance On GLP-1 Demand

Eli Lilly recently reported that second-quarter 2026 sales rose to about US$23.0 billion with net income of roughly US$7.10 billion, and the company raised its full-year 2026 revenue guidance to US$85.0 billion–US$87.0 billion from US$82.0 billion–US$85.0 billion. Management attributed this step-up in outlook largely …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction

Eli Lilly and Company LLY used its Q2 2026 earnings call to pair a higher revenue outlook with broader access for its obesity portfolio. Management highlighted accelerating Foundayo adoption, early Medicare Bridge traction and a planned 2027 retatrutide filing. Non-GAAP earnings of $8.38 per …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Eli Lilly and Company will release its second-quarter earnings report before the opening bell on Wednesday, Aug. 5. Analysts expect the company to report quarterly earnings of …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drugmaker dominating the obesity and diabetes market, cranked up its 2026 revenue forecast after another monster quarter, sending the stock more than 5% higher in early U.S. trading. Management now expects annual revenue of …

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain. Continue Reading

LILY34 main company
Sharemaestro market context Trend signal active 52 weeks +61.7% LILY34 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context